🎉 M&A multiples are live!
Check it out!

BioAtla Valuation Multiples

Discover revenue and EBITDA valuation multiples for BioAtla and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

BioAtla Overview

About BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise  mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.


Founded

2007

HQ

United States of America
Employees

61

Website

bioatla.com

Financials

LTM Revenue $7.8M

LTM EBITDA n/a

EV

-$29.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BioAtla Financials

BioAtla has a last 12-month revenue of $7.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, BioAtla achieved revenue of $11.0M and an EBITDA of -$73.0M.

BioAtla expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BioAtla valuation multiples based on analyst estimates

BioAtla P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $11.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$128M -$73.0M XXX XXX XXX
EBITDA Margin -Infinity% -664% XXX XXX XXX
Net Profit -$106M -$123M XXX XXX XXX
Net Margin -Infinity% -1122% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

BioAtla Stock Performance

As of April 15, 2025, BioAtla's stock price is $0.

BioAtla has current market cap of $18.4M, and EV of -$29.8M.

See BioAtla trading valuation data

BioAtla Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$29.8M $18.4M XXX XXX XXX XXX $-1.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BioAtla Valuation Multiples

As of April 15, 2025, BioAtla has market cap of $18.4M and EV of -$29.8M.

BioAtla's trades at -3.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate BioAtla's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BioAtla and 10K+ public comps

BioAtla Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$29.8M XXX XXX XXX
EV/Revenue -2.7x XXX XXX XXX
EV/EBITDA 0.4x XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioAtla Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BioAtla Valuation Multiples

BioAtla's NTM/LTM revenue growth is -100%

BioAtla's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, BioAtla's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BioAtla's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BioAtla and other 10K+ public comps

BioAtla Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -664% XXX XXX XXX XXX
EBITDA Growth -43% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 199% XXX XXX XXX XXX
R&D Expenses to Revenue 574% XXX XXX XXX XXX
Opex to Revenue 772% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BioAtla Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BioAtla M&A and Investment Activity

BioAtla acquired  XXX companies to date.

Last acquisition by BioAtla was  XXXXXXXX, XXXXX XXXXX XXXXXX . BioAtla acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BioAtla

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BioAtla

When was BioAtla founded? BioAtla was founded in 2007.
Where is BioAtla headquartered? BioAtla is headquartered in United States of America.
How many employees does BioAtla have? As of today, BioAtla has 61 employees.
Who is the CEO of BioAtla? BioAtla's CEO is Dr. Jay M. Short,PhD.
Is BioAtla publicy listed? Yes, BioAtla is a public company listed on NAS.
What is the stock symbol of BioAtla? BioAtla trades under BCAB ticker.
When did BioAtla go public? BioAtla went public in 2020.
Who are competitors of BioAtla? Similar companies to BioAtla include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of BioAtla? BioAtla's current market cap is $18.4M
What is the current revenue of BioAtla? BioAtla's last 12-month revenue is $7.8M.
What is the current EV/Revenue multiple of BioAtla? Current revenue multiple of BioAtla is -3.8x.
Is BioAtla profitable? Yes, BioAtla is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.